
    
      1. Primary objectives

           â™¦ To determine the Maximum Tolerated Dose (MTD) of NC-6004 according to the Dose
           Limiting Toxicity (DLT) in combination with 5-FU plus cetuximab as firstline treatment
           in patients with recurrent and/or metastatic squamous cell carcinoma of the head and
           neck (SCCHN), and to decide the RD for the following studies

        2. Secondary objectives 1). To evaluate the safety and tolerability profile of NC-6004 in
           combination with 5- FU plus cetuximab 2). To assess the pharmacokinetic effects of
           NC-6004 3). To assess the antitumor effects of NC-6004
    
  